Mechanisms of corneal allograft rejection

    Research output: Contribution to journalArticlepeer-review

    88 Citations (Scopus)


    More effective therapies are required to improve clinical corneal allograft outcomes. The strategies that have led to improvements in vascularized organ graft survival are not always applicable to the cornea. New treatments that modulate the afferent arm of the immune response to a corneal allograft are more likely to prove effective than are treatments that target the effector arm of the immune response. We briefly discuss two such options: the use of engineered antibody fragments to block antigen presentation, and the use of gene therapy approaches to abrogate antigen presenting-cell function.

    Original languageEnglish
    Pages (from-to)S165-S168
    Number of pages4
    JournalThe Ocular Surface
    Issue number4
    Publication statusPublished - 2005


    • Antigen presentation
    • Corneal transplantation
    • Engineered antibodies
    • Gene transfer
    • Rejection


    Dive into the research topics of 'Mechanisms of corneal allograft rejection'. Together they form a unique fingerprint.

    Cite this